Benzinga | Jan 12, 2021 07:07AM EST

SVB Leerink Maintains Outperform on Zymeworks, Raises Price Target to $66

SVB Leerink analyst Andrew Berens maintains Zymeworks (NYSE:ZYME) with a Outperform and raises the price target from $45 to $66.